Article Versions Notes

Takenaka J, Watanabe S, Abe T, Takeuchi S, Hirata K, Kimura R, Ishii H, Wakabayashi N, Majigsuren M, Kudo K. Urinary Dopamine Levels Can Predict the Avidity of Post-Therapy [¹³¹I]MIBG Scintigraphy in Unresectable or Metastatic Pheochromocytomas and Paragangliomas: A Preliminary Clinical Study. Pharmaceuticals. 2025; 18(2):165. https://doi.org/10.3390/ph18020165

Takenaka, Junki, Shiro Watanabe, Takashige Abe, Satoshi Takeuchi, Kenji Hirata, Rina Kimura, Hiroshi Ishii, Naoto Wakabayashi, Mungunkhuyag Majigsuren, and Kohsuke Kudo. 2025. "Urinary Dopamine Levels Can Predict the Avidity of Post-Therapy [¹³¹I]MIBG Scintigraphy in Unresectable or Metastatic Pheochromocytomas and Paragangliomas: A Preliminary Clinical Study" Pharmaceuticals 18, no. 2: 165. https://doi.org/10.3390/ph18020165

Takenaka, J., Watanabe, S., Abe, T., Takeuchi, S., Hirata, K., Kimura, R., Ishii, H., Wakabayashi, N., Majigsuren, M., & Kudo, K. (2025). Urinary Dopamine Levels Can Predict the Avidity of Post-Therapy [¹³¹I]MIBG Scintigraphy in Unresectable or Metastatic Pheochromocytomas and Paragangliomas: A Preliminary Clinical Study. Pharmaceuticals, 18(2), 165. https://doi.org/10.3390/ph18020165